Prevents osteoporosis in postmenopausal women ( 1.1, 1.2 ). ANDA 90258, held by Hangzhou Binjiang. Alendronate Sodium.
As of Nov 16, 2026, ANDA 90258 (Alendronate Sodium), held by Hangzhou Binjiang, was first approved by FDA on Sep 24, 2009, with 4 approved supplements and 0 published complete response letters.
Alendronate sodium is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women ( 1.1, 1.2 ) Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget's disease of bone Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. 1.1 Treatment of Osteoporosis in Postmenopausal Women Alendronate sodium tablets, USP are indicated for the treatment of osteoporosis in postmenopausal women.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2009 | Original application | Approved | None posted |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Rx |
| Apr 18, 2017 | Supplement 10Manufacturing | Approved | None posted |
| Mar 29, 2013 | Supplement 2Manufacturing | Approved | None posted |
| Sep 26, 2012 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 16, 2012 | Supplement 4Labeling | Approved | None posted |
| Sep 24, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters